BioAffinity Total Other Income Expense Net from 2010 to 2024

BIAFW Stock  USD 0.75  0.15  24.40%   
BioAffinity Technologies Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, BioAffinity Technologies Total Other Income Expense Net regression line of quarterly data had r-squared of  0.18 and coefficient of variation of (172.93). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
57.2 K
Current Value
60.1 K
Quarterly Volatility
1.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BioAffinity Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 262.1 K, Interest Expense of 35.3 K or Gross Profit of 831.2 K, as well as many indicators such as Price To Sales Ratio of 4.82, Dividend Yield of 0.0 or PTB Ratio of 2.78. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies Valuation or Volatility modules.
  
Check out the analysis of BioAffinity Technologies Correlation against competitors.

Latest BioAffinity Technologies' Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of bioAffinity Technologies Warrant over the last few years. It is BioAffinity Technologies' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioAffinity Technologies' overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

BioAffinity Total Other Income Expense Net Regression Statistics

Arithmetic Mean(994,877)
Coefficient Of Variation(172.93)
Mean Deviation1,324,695
Median(212,059)
Standard Deviation1,720,463
Sample Variance3T
Range4.7M
R-Value(0.42)
Mean Square Error2.6T
R-Squared0.18
Significance0.12
Slope(161,047)
Total Sum of Squares41.4T

BioAffinity Total Other Income Expense Net History

202460.1 K
202357.2 K
2022-4.1 M
2021-4.1 M
2020-4.7 M

About BioAffinity Technologies Financial Statements

BioAffinity Technologies investors use historical fundamental indicators, such as BioAffinity Technologies' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioAffinity Technologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net57.2 K60.1 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.